MENG FANG¹, JING GUO¹, HAIPING WANG¹, ZICHANG YANG², HAN ZHAO^1,*, QINGJIA CHI²

BIOCELL, Vol.46, No.2, pp. 401-415, 2022, DOI:10.32604/biocell.2022.016989

Abstract Hepatocellular carcinoma (HCC) is a common immunogenic malignant tumor. Although the new strategies of immunotherapy and targeted therapy have made considerable progress in the treatment of HCC, the 5-year survival rate of patients is still very low. The identification of new prognostic signatures and the exploration of the immune microenvironment are crucial to the optimization and improvement of molecular therapy strategies. We studied the potential clinical benefits of the inflammation regulator miR-93-3p and mined its target genes. Weighted gene co-expression network analysis (WGCNA), univariate and multivariate COX regression and the LASSO COX algorithm are employed to identify prognostic-related genes and… More >

XINGHONG YAO^1,2,#, CHENGQUAN LU^3,#, JUNYI SHEN¹, WENLI JIANG¹, YAN QIU¹, YE ZENG^1,*, LIANG LI^1,*

BIOCELL, Vol.45, No.6, pp. 1425-1448, 2021, DOI:10.32604/biocell.2021.017289

Abstract Cancer stem cells (CSCs) are heterogeneous with self-renewal and differentiation ability. The mRNA expression-based stemness index (mRNAsi) described the similarity between tumor cells and CSCs, which is positively associated with the poor prognosis of cancer patients. However, the key prognostic genes related to mRNAsi in hepatocellular carcinoma (HCC) remains unclear. A 9-gene signature related to mRNAsi and HCC prognosis including PSMG3, SNRPD1, DTYMK, PIGU, NME1, TXNL4A, IPO4, PES1, and REXO4 was obtained. High expression of this signature indicates poor prognosis of HCC. PIGU was an independent prognostic factor of HCC, which was significantly associated with progression of HCC. Among them,… More >